Project description:Primary objectives: The primary objective is to investigate circulating tumor DNA (ctDNA) via deep sequencing for mutation detection and by whole genome sequencing for copy number analyses before start (baseline) with regorafenib and at defined time points during administration of regorafenib for treatment efficacy in colorectal cancer patients in terms of overall survival (OS).
Primary endpoints: circulating tumor DNA (ctDNA) via deep sequencing for mutation detection and by whole genome sequencing for copy number analyses before start (baseline) with regorafenib and at defined time points during administration of regorafenib for treatment efficacy in colorectal cancer patients in terms of overall survival (OS).
Project description:Three-spot angelfish (Apolemichthys trimaculatus) is one of the most widespread angelfish that belongs to Pomacanthidae. However, there are few reports of the systemically classification and evolutionary analysis for A. trimaculatus so far. In this study, the complete mitochondrial genome of the A. trimaculatus is described. The full length of the mitogenome is 16,548 bp, consisting of 13 protein-coding genes, 22 transfer RNAs, two ribosomal RNAs genes, and a non-coding control region. The overall base composition is 28.4% for A, 25.6% for T, 29.5% for C, and 16.5% for G, with a slight AT bias (54.0%). The mitogenome of A. trimaculatus provided essential and valuable DNA molecular information for further phylogeny and management of angelfish species.
Project description:The study is intended to collect specimens to support the application of genome analysis technologies, including large-scale genome sequencing. This study will ultimately provide cancer researchers with specimens that they can use to develop comprehensive catalogs of genomic information on at least 50 types of human cancer. The study will create a resource available to the worldwide research community that could be used to identify and accelerate the development of new diagnostic and prognostic markers, new targets for pharmaceutical interventions, and new cancer prevention and treatment strategies. This study will be a competitive enrollment study conducted at multiple institutions.
